CASI Pharmaceuticals, Inc. (CASI)の価格はいくらですか

CASI Pharmaceuticals, Inc. (CASI)の価格は$0.15です

CASI Pharmaceuticals, Inc. (CASI)の時価総額は何ですか

CASI Pharmaceuticals, Inc. (CASI)の時価総額は$2.33Mです

CASI Pharmaceuticals, Inc.（CASI）株式分割

CASI Pharmaceuticals, Inc. is a biopharmaceutical firm focused on the development and market introduction of medical treatments and drugs across China, the United States, and globally. Its marketed product, EVOMELA, is an intravenous formulation of melphalan, utilized for conditioning prior to stem cell transplantation and as a palliative option for patients suffering from multiple myeloma. The company's developmental pipeline encompasses several experimental therapies. This includes CNCT19, an investigational autologous CD19 CAR-T therapy aimed at treating patients with B-cell acute lymphoblastic leukemia (B-ALL) and B-cell non-Hodgkin lymphoma (B-NHL). BI-1206 is currently in Phase I/II trials, combined with the anti-PD1 therapy Keytruda, for solid tumors, and is also undergoing a Phase I/IIa study in conjunction with MabThera (rituximab) for individuals with relapsed/refractory NHL. CB-5339 is advancing through Phase I clinical trials for acute myeloid leukemia and myelodysplastic syndrome. Further additions to its pipeline are CID-103, targeting multiple myeloma patients, and Thiotepa, which possesses a broad range of indications, including its use as a conditioning therapy for various allogeneic hematopoietic stem cell transplants. Additionally, long-acting injectable formulations of Octreotide are being developed for managing acromegaly and alleviating symptoms associated with different neuroendocrine tumors. CASI maintains licensing agreements with Juventas Cell Therapy Ltd, BioInvent International AB, Black Belt Therapeutics Limited, and Cleave Therapeutics, Inc. It has also forged distribution partnerships with China Resources Pharmaceutical Commercial Group International Trading Co., Ltd, Pharmathen Global BV, and Riemser Pharma GmbH. Incorporated in 1991, this Rockville, Maryland-based company was formerly known as EntreMed, Inc. before adopting its current name, CASI Pharmaceuticals, Inc., in June 2014.

年	株式分割	分割比率	累積分割比率
提供された日付のデータは十分ではありません。

年

株式分割

分割比率

累積分割比率

提供された日付のデータは十分ではありません。

企業	株式分割の回数	累積分割比率	国
Vertex Pharmaceuticals Incorporated VRTX.US	1	x2	US
Argenx SE ARGX.US	0	-	NL
Lonza Group AG LONN.SW	0	-	CH
Samsung Biologics Co.,Ltd. 207940.KS	0	-	KR
UCB S.A. UCB.BR	0	-	BE

企業

株式分割の回数

累積分割比率

国